Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

461
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
461
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

414
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
414
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.

American heart journal·2018
Same author

Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Journal of the American Heart Association·2018
Same author

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal of the American College of Cardiology·2018
Same author

Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.

European journal of heart failure·2018
Same author

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.

JACC. Heart failure·2018
Same author

The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All.

Journal of the American College of Cardiology·2018

相关实验视频

Updated: Jan 17, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.6K

开发用于罕见心血管疾病的治疗方法.

Joseph B Lerman1, Dwight D Koeberl2, Shilpi Epstein3

  • 1Duke Clinical Research Institute, Durham, NC.

American heart journal
|September 14, 2025
PubMed
概括

开发用于罕见心血管疾病的治疗方法面临的挑战包括诊断和小患者组. 近年来,在治疗这些罕见的心脏病方面取得了进展.

更多相关视频

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

相关实验视频

Last Updated: Jan 17, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.6K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

科学领域:

  • 心脏病学 心脏病学
  • 罕见疾病 罕见疾病
  • 药物开发 药物开发

背景情况:

  • 罕见的心血管疾病总体影响全球数百万人,导致严重的发病率和死亡率.
  • 大多数罕见的心血管疾病目前缺乏经批准的治疗干预措施.
  • 这些情况在研究和治疗开发中带来了独特的挑战.

研究的目的:

  • 为开发罕见心血管疾病治疗方法所面临的挑战提供概述.
  • 突出推进罕见心血管疾病治疗领域的潜在策略.
  • 审查过去十年取得的进展.

主要方法:

  • 对罕见心血管疾病治疗发展中的挑战和策略的文献综述.
  • 对障碍的分析,包括诊断,队列大小,终点,伦理和成本.
  • 检查最近成功的治疗发展.

主要成果:

  • 确定了主要挑战:诊断延迟,小患者队列,终点选择,伦理/监管问题和高治疗成本.
  • 尽管面临挑战,但在过去十年中,罕见心血管疾病治疗开发的成功率显著增加.
  • 克服这些障碍的策略对于未来的进步至关重要.

结论:

  • 对罕见心血管疾病的治疗开发是复杂的,但可以实现的.
  • 克服诊断,后勤和财务障碍是非常重要的.
  • 持续的创新和战略方法正在推进罕见心脏病的治疗选择.